AbbVie

AbbVie pairs up another ADC cancer drug with Bristol-Myers Squibb's Opdivo
AbbVie pairs up another ADC cancer drug with Bristol-Myers Squibb's Opdivo
Fierce Biotech
AbbVie
Bristol-Myers Squibb
Opdivo
ABBV-399
antibody-drug conjugate
non-small cell lung cancer
Flag link:
AbbVie’s top execs paint a rosy pic of the mega-blockbuster future looming for Humira and PhIII drugs
AbbVie’s top execs paint a rosy pic of the mega-blockbuster future looming for Humira and PhIII drugs
Endpoints
AbbVie
Humira
Rick Gonzalez
Flag link:
AbbVie, Roche to seek broader market for leukemia drug after trial success
AbbVie, Roche to seek broader market for leukemia drug after trial success
BioPharma Dive
AbbVie
Roche
clinical trials
Venclexta
Rituxan
chronic lymphocytic leukemia
Flag link:
Which of These 5 Will Be the Best-Selling Drug Worldwide in 2020?
Which of These 5 Will Be the Best-Selling Drug Worldwide in 2020?
Motley Fool
AbbVie
Humira
Celgene
Revlimid
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
Biogen
aducanumab
Flag link:
AbbVie keen on JAK inhibitor despite safety concerns
AbbVie keen on JAK inhibitor despite safety concerns
BioPharma Dive
AbbVie
JAK inhibitors
Upadacitinib
ABT-494
rheumatoid arthritis
Flag link:
AbbVie and Pfizer hover at top, J&J Stelara surges in August TV pharma ad spend
AbbVie and Pfizer hover at top, J&J Stelara surges in August TV pharma ad spend
Fierce Pharma
AbbVie
Pfizer
JNJ
drug ads
television ads
Flag link:
AbbVie reports two patient deaths in rheumatoid arthritis study
AbbVie reports two patient deaths in rheumatoid arthritis study
Yahoo/Reuters
AbbVie
clinical trials
rheumatoid arthritis
Upadacitinib
ABT-494
Flag link:
AbbVie preps JAK atopic dermatitis candidate for phase 3
AbbVie preps JAK atopic dermatitis candidate for phase 3
Fierce Biotech
AbbVie
JAK inhibitors
clinical trials
atopic dermatitis
Upadacitinib
Sanofi
Regeneron
Dupixent
Flag link:
This Shield of Patents Protects the World’s Best-Selling Drug
This Shield of Patents Protects the World’s Best-Selling Drug
Bloomberg
patents
AbbVie
Humira
Flag link:
AbbVie adds more stellar data on ABT-494 — this time for atopic dermatitis
AbbVie adds more stellar data on ABT-494 — this time for atopic dermatitis
Endpoints
AbbVie
ABT-494
atopic dermatitis
Upadacitinib
Flag link:
Infographic | The leaders of the global hepatitis-C market
Infographic | The leaders of the global hepatitis-C market
Medical Marketing and Media
hepatitis C
Gilead Sciences
Merck
AbbVie
Bristol-Myers Squibb
Flag link:
Pharma Stocks That Could Move On New Data
Pharma Stocks That Could Move On New Data
Barron's
pharma stocks
AbbVie
Bayer
Novartis
Bristol-Myers Squibb
Eli Lilly
European Society of Cardiology
Flag link:
Biogen, Samsung Humira copy wins EU approval
Biogen, Samsung Humira copy wins EU approval
Fierce Pharma
Biogen
Samsung Bioepis
Europe
Humira
AbbVie
Imraldi
biosimilars
Flag link:
The decade's top 10 patent losses, worth a whopping $915B in lifetime sales
The decade's top 10 patent losses, worth a whopping $915B in lifetime sales
Fierce Pharma
patents
AbbVie
Humira
Pfizer
Lipitor
Norvasc
GSK
Advair
Sanofi
Lantus
JNJ
Remicade
AstraZeneca
Crestor
Nexium
Amgen
Neulasta
Novartis
Diovan
Flag link:
The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results
The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results
Fierce Pharma
pharma stocks
Merck
Pfizer
AbbVie
Eli Lilly
Bristol-Myers Squibb
GSK
Roche
Sanofi
Bayer
Novo Nordisk
Celgene
Biogen
AstraZeneca
Flag link:
AbbVie’s new, cheaper hepatitis C drug could launch the drug world’s own Hunger Games
AbbVie’s new, cheaper hepatitis C drug could launch the drug world’s own Hunger Games
Marketwatch
AbbVie
hepatitis C
Mavyret
Gilead Sciences
Merck
Flag link:
Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?
Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?
Motley Fool
AbbVie
Gilead Sciences
hepatitis C
Mavyret
Flag link:
AbbVie's new pan-genotypic hepatitis C drug Mavyret deeply underprices the competition
AbbVie's new pan-genotypic hepatitis C drug Mavyret deeply underprices the competition
Fierce Pharma
AbbVie
hepatitis C
Mavyret
drug pricing
Flag link:
J&J, AbbVie's Imbruvica breaks out of blood-cancer corner with new graft-versus-host approval
J&J, AbbVie's Imbruvica breaks out of blood-cancer corner with new graft-versus-host approval
Fierce Pharma
JNJ
AbbVie
Imbruvica
graft vs host disease
FDA
Flag link:
AbbVie confident in strategy as Humira mints money
AbbVie confident in strategy as Humira mints money
BioPharma Dive
AbbVie
Humira
Flag link: